Although not currently approved, PSMA directed radioligand therapies with Lutetium-177 (177Lu-PSMA-617; 177Lu-PSMA-I&T) or Actinium-225 (225Ac-PSMA-617) or others are under investigation within clinical trials and are also used off-label for treatment of refractory metastatic prostate cancer 13-19. The gene discussed is FOLH1; the disease is metastatic prostate carcinoma.